The call, on record
HIMS bullish call
Quoted text as recorded“I think they could do that by 2029, maybe even 2028 with a stretch goal, that's going to make this a great value stock and a growth stock.”@ 11:38 · open at this moment on YouTube ↗
Our interpretation
- Source published
- Aug 11, 2026
- Timeframe
- by 2029, maybe 2028
- Extracted deadline
- Dec 31, 2029
- Interpreted confidence
- low
- Specificity
- vague
Why this call is unscored
- Status
- Not scored
- Notes
- There is no numerical target that can be objectively scored.
Email me when HIMS calls resolve
When a tracked HIMS call is scored — hit, miss or partial — we’ll email you the result. No account needed.
Used only for these updates. Privacy
Our summary of the thesis
Strongly BullishStructured interpretation of the video, not a verbatim quotation. Check the source for conditions, emphasis and context.
Travis views Hims & Hers as the biggest holding in his portfolio, believing the company is deliberately sacrificing short-term margins to acquire subscribers and build a long-term healthcare aggregator platform. He argues the recent stock drop is a short-term overreaction to margin compression, while the underlying growth trajectory (accelerating revenue, subscriber adds, expanding treatment categories) is strengthening.
Key arguments
- Subscribers grew over 300,000 sequentially to 2.89 million, partly boosted by the Eucalyptus acquisition
- Monthly revenue per subscriber jumped from $8 to $92 due to GLP1 weight loss products via Novo Nordisk and Eli Lilly deals
- Full-year revenue guidance raised to $3.1-3.3 billion from $2.8-3.0 billion, with 50%+ growth expected in the second half of 2026
- International expansion (Eucalyptus, Zava, Canada) is driving growth beyond the US market
- Customer acquisition economics improve over time as cumulative gross profit per customer builds each quarter, similar to software company lifetime-value models
- Long-term aggregator thesis: adding specialties like peptides and hormone health will keep expanding subscriber base toward 5-20 million
Counter-arguments acknowledged
- Gross margin fell from ~80% to 63.8% due to lower-margin branded GLP1 products
- Adjusted EBITDA margin guidance was cut from ~11% to 9%, and the high end of EBITDA guidance was reduced from $350 million to $325 million
- Legal reserves tied to an FTC issue are weighing on near-term margins
- Stock fell about 7% after hours and remained down roughly 2.8% pre-market on the margin disappointment
Hedges and caveats (from the video)
- Short-term market reaction negative despite long-term bullish thesis
- Margin compression expected due to customer acquisition cost investments
- Growth-versus-profitability trade-off creates investor uncertainty
- Presenter acknowledges tension between growth and near-term profitability
- Stock down 7% after earnings despite positive long-term outlook
About this record
Not yet reviewed by a moderatorAI-extracted record. A quote, summary and outcome each need their own context. Moderator review does not certify investment performance.
- Source published
- Aug 11, 2026, 2:49 PM UTC
- First recorded by TubeRank
- Aug 11, 2026, 3:18 PM UTC
- Record last updated
- Oct 6, 2026, 6:32 AM UTC
- Moderator review recorded
- Not recorded
- Transcript provenance
- YouTube captions (manual or automatic)
- Recorded analysis processor/source label
- claude-sonnet-5
- This can identify a workflow rather than an exact AI model version.
- Extraction pipeline version
- v1.0.0
- Outcome methodology version
- 2026-10-06.5
- Outcome reason code
- missing_target
Recent record changes 5 shown
Oct 6, 2026, 6:32 AM UTC
corrected
- Outcome methodology version
Before2026-10-06.4
After2026-10-06.5
Oct 6, 2026, 5:25 AM UTC
corrected
- Source moment (seconds)
BeforeNot recorded
After698
Oct 6, 2026, 5:14 AM UTC
corrected
- Outcome methodology version
Before2026-10-06.2
After2026-10-06.4
Oct 6, 2026, 4:00 AM UTC
corrected
- Outcome methodology version
Before2026-10-06.1
After2026-10-06.2
Oct 6, 2026, 3:27 AM UTC
missing target
- Outcome methodology version
BeforeNot recorded
After2026-10-06.1
- Recorded outcome date
BeforeNot recorded
After2026-10-06
- Outcome explanation
BeforeNot recorded
AfterThere is no numerical target that can be objectively scored.
- Outcome reason
BeforeNot recorded
AfterMissing target
Showing up to 20 recent changes. The complete feed has 6 recorded events for this call, including its initial entry. Read the full paginated history (JSON); follow nextCursor while hasMore is true.
Stored outcome evidence
- Stored reference price
- Not recorded
- Not recorded · provider not recorded
- Target as extracted
- Not recorded
- Stated deadline as extracted
- Dec 31, 2029
- Recorded outcome date
- Oct 6, 2026
- Outcome price observation
- Not recorded
- Not recorded · provider not recorded
Stored explanation
There is no numerical target that can be objectively scored.
Missing timestamps, providers and versions are historical gaps. Stored observations can include daily closes; they do not show every intraday touch or prove an executable trade. Read the methodology.
Why we interpreted the confidence this way
Heavily hedged with 'could', 'maybe', and 'stretch goal', indicating low commitment despite a directional bullish view on hitting revenue/EBITDA targets early.